J. Molner AS (Nasdaq Tallinn: MOLNR) today announced the launch of Clobetasol Propionate Cream USP, 0.05% (Emollient) in the United States. The launch represents another step in the Company’s strategy to expand its dermatology portfolio and strengthen its international presence. This is the Company’s fourth precription drug product launched in the United States.
Clobetasol Propionate Cream USP, 0.05% (Emollient) is a prescription-only super-potent corticosteroid medication indicated for the relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
“J. Molner AS is the developer of Clobetasol Propionate Cream USP, 0.05% (Emollient), which we brought to market together with our partner holding the ANDA. Our team ensured that all regulatory and quality requirements were met to reintroduce the product to the US market in compliance with FDA standards,” said Jason Grenfell-Gardner, Founder of J. Molner AS.
J. Molner AS remains dedicated to building long-term growth through expanding its pharmaceutical portfolio and delivering high-quality treatment solutions to patients and healthcare providers worldwide.
For additional information about J. Molner AS, please visit www.jmolner.com.